OrthoSera Medical is a clinical-stage regenerative medicine company, which utilizes the power of blood serum as a therapeutic tool.
OrthoSera’s core technology is a proprietary human serum formulation that is translated to products regulated as tissues, devices or blood derivatives. The company currently focuses on bone grafting, osteoarthritis and wound healing in dental and orthopedic indications.
Blood serum is physiological growth factor-rich biologic that has a powerful regenerative capacity. Orthosera’s propritetary serum fraction (hyperacute serum or hypACT™) is even more specific as it retains all regenerative capacities while minimizing the pro-inflammatory components.
Extensive research shows that hyperacute serum outperforms all other blood derivatives such as PRP varieties in promoting cell proliferation without affecting lineage.
BoneAlbumin™ is essentially a serum albumin-enhanced bone graft that has been shown to activate bone marrow stem cells, resulting in faster and better bone healing. This tissue product is now available and clinical studies are proving its effectiveness in sports surgery and dental treatments.
Hyperacute serum or hypACT™ is a patented technology that has shown an outstanding effect in promoting osteoarthritic bone, cartilage and mesenchymal cell proliferation. It is currently under clinical evaluation as an autologous treatment for knee osteoarthritis. Development is underway to replace the autologous blood product with an allogeneic, off-the-shelf serum with unparalleled efficacy and clinical utility. Understanding the complex nature of degenerative joint diseases OrthoSera develops companion diagnostic tools to optimize patient selection for serum therapies.
OrthoSera was actively involved in the fight against the COVID19 pandemic by offering its expertise and technical capacity during the coronavirus outbreak in Hungary. OrthoSera pioneered the convalescent plasma treatment against SARS2-CoV.
Latest news
Plasma donation in Budapest
Plasma donation at the University of Physical Education. Thirty volunteers, donors came forward and offered to help. https://www.youtube.com/watch?v=P2WQHbdRDGo
Establishment of Lacerta Technologies GmbH-Successful seed financing
Krems an der Donau, Austria, 16 November 2012 – Lacerta Technologies GmbH has been successfully established in Krems an der...
Albumin Bone Graft Patent Granted in the US – Important milestone in Lacerta’s IP strategy
Krems an der Donau, Austria, 4 September 2013 – The United States Patent Office has granted the patent entitled “Method for producing...
New Chief Business Officer at Lacerta Technologies GmbH
Krems an der Donau, Austria, 30th January 2014 – Lacerta Technologies has hired a new Chief Business Officer to strengthen...
Research Article was published on Increased Release Time of Antibiotics from Bone Allografts through a Novel Biodegradable Coating
Krems an der Donau, Austria, 22nd July 2014 – Lacerta Technologies has published a research article in cooperation withSemmelweis University and Singapore...